110017 ⎘
dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
ONCOLYTIC VIRUS SIMULTANEOUSLY EXPRESSING CD55 AND CD59
#2SELF-AMPLIFYING MESSENGER RNA
#3Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#4ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
#5RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#6Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#7Engineered immunostimulatory bacterial strains and uses thereof
#8HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT
#9TARGETING MOIETY-DECORATED ONCOLYTIC VIRUSES
#10Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
#11Enhanced systems for cell-mediated oncolytic viral therapy
#12Engineered immunostimulatory bacterial strains and uses thereof
#13Generation of Tumor Endothelium Specific Viruses
#14Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#15Method for protecting liver and a liver protecting agent
#16Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles
#17Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
#18SUPPRESSORS OF MATURE T CELLS
#19Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
#20Incorporation of the B18R gene to enhance antitumor effect of virotherapy